S 4472: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

S 4472 in plain English: This bill reauthorizes through FY2031 federal programs supporting research and development of drugs and therapies for ALS (Lou Gehrig's disease) and other neurodegenerative diseases. It continues grants through the NIH and FDA and maintains a Public-Private Partnership focused on treatment development and regulatory review. The bill also adds new oversight requirements, including safety reporting rules and a recurring FDA planning process.

Stated purpose

This bill reauthorizes through fiscal year 2031 the programs that fund research and development of treatments for ALS (Lou Gehrig's disease) and other neurodegenerative diseases, and updates those programs with new safety reporting and planning requirements.

Key points

• Reauthorizes NIH grants for ALS investigational drug research through FY2031, with new safety and efficacy review requirements
• Reauthorizes FDA grants for ALS and other neurodegenerative disease therapy research and development through FY2031
• Reauthorizes a Public-Private Partnership between the FDA and NIH to support neurodegenerative disease treatment development
• Requires the FDA to publish a five-year action plan every five years on ALS and rare neurodegenerative disease drug access
• Requires GAO and HHS to report on the impacts of these grant programs

Arguments supporters make

• ALS is a fatal disease with very few treatment options, and continuing this funding keeps life-extending experimental therapies available to patients who have no other options.
• The new safety reporting and enrollment timeline requirements make the program more accountable and help ensure that grant money is tied to real scientific progress.
• Requiring the FDA to publish and update a public action plan every five years gives patients, researchers, and Congress a clearer picture of what is being done and where gaps remain.

Arguments opponents make

• Reauthorizing and expanding federal grant programs increases government spending without a guarantee that the funded research will produce effective treatments, raising questions about fiscal responsibility.
• Adding new reporting and data requirements on grantees and the FDA could create bureaucratic burdens that slow down the very research the bill is meant to accelerate.
• Focusing resources on ALS and selected neurodegenerative diseases, rather than broader research priorities, means other serious conditions may receive less attention or funding.

Tradeoffs

Extending and expanding these programs may speed access to experimental therapies for a small group of critically ill patients, but it requires sustained federal spending and new administrative obligations that could stretch agency resources or redirect them from other health priorities.

Current status in Congress: Passed Senate.

NewsClear — neutral news & congressional tracking · Bill of the Week